|Bid||81.52 x 1400|
|Ask||84.16 x 1400|
|Day's Range||75.88 - 89.48|
|52 Week Range||43.86 - 202.73|
|Beta (5Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 23, 2022 - Feb. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||174.56|
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.
With every new year comes a clean slate. For Cathie Wood’s Ark Invest, that doesn’t seem to be the case. The firm’s beaten-down Ark Innovation Fund fund has hit a new low in 2022 – already.